SMYD3 and cancer: We found that restoring the expression of WT SMYD3 reduced cancer cell sensitivity to 5-fluorouracil, irinotecan, and oxaliplatin, resulting in drug tolerance levels comparable to those observed in the parental cell line (Fig. 3G).